State-of-the-Art in the Drug Discovery Pathway for Chagas Disease: A Framework for Drug Development and Target Validation

Tolerance and Adherence of Patients with Chronic Chagas Disease Treated with Benznidazole

(2023) Cristina Vázquez et al.   Revista da Sociedade Brasileira de Medicina Tropical

3Rs Principle and Legislative Decrees to Achieve High Standard of Animal Research

(2023) Paolo Verderio et al.   Animals

Impact of Laboratory-Adapted Intracellular Trypanosoma cruzi Strains on the Activity Profiles of Compounds with Anti-T. cruzi Activity

(2023) Melissa L. Sykes et al.   Microorganisms

The Search for Biomarkers and Treatments in Chagas Disease: Insights From TGF-Beta Studies and Immunogenetics

(2022) Roberto Rodrigues Ferreira et al.   Frontiers in Cellular and Infection Microbiology

Experimental Combination Therapy with Amiodarone and Low-Dose Benznidazole in a Mouse Model of Trypanosoma cruzi Acute Infection

(2022) Juliana Magalhães Chaves Barbosa et al.   Microbiology Spectrum

Antiparasitic treatment with itraconazole and amiodarone in 2 dogs with severe, symptomatic Chagas cardiomyopathy

(2022) Elizabeth L. Malcolm et al.   JOURNAL OF VETERINARY INTERNAL MEDICINE

ColabFold: making protein folding accessible to all

(2022) Milot Mirdita et al.   NATURE METHODS

A phase-2, randomized, multicenter, placebo-controlled, proof-of-concept trial of oral fexinidazole in adults with chronic indeterminate Chagas disease

(2022) Faustino Torrico et al.   CLINICAL INFECTIOUS DISEASES

The Use of AlphaFold for In Silico Exploration of Drug Targets in the Parasite Trypanosoma cruzi

(2022) Albert Ros-Lucas et al.   Frontiers in Cellular and Infection Microbiology

Diffuse Myocardial Fibrosis and Cardiomyocyte Diameter Are Associated With Heart Failure Symptoms in Chagas Cardiomyopathy

(2022) Cristiane Nardi Gemme et al.   Frontiers in Cardiovascular Medicine

Anti-trypanosomatid structure-based drug design – lessons learned from targeting the folate pathway

(2022) Joanna Panecka-Hofman et al.   Expert Opinion on Drug Discovery

Benchmarking AlphaFold ‐enabled molecular docking predictions for antibiotic discovery

(2022) Felix Wong et al.   Molecular Systems Biology

Anti-trypanosomatid drug discovery: progress and challenges

(2022) Manu De Rycker et al.   NATURE REVIEWS MICROBIOLOGY

Comparing in vivo bioluminescence imaging and the Multi-Cruzi immunoassay platform to develop improved Chagas disease diagnostic procedures and biomarkers for monitoring parasitological cure

(2022) Amanda Fortes Francisco et al.   PLoS Neglected Tropical Diseases

Discovery of an orally active benzoxaborole prodrug effective in the treatment of Chagas disease in non-human primates

(2022) Angel M. Padilla et al.   Nature Microbiology

Animal Models of Trypanosoma cruzi Congenital Transmission

(2022) Eduardo E. Avalos-Borges et al.   Pathogens

Efficacy and safety of acoziborole in patients with human African trypanosomiasis caused by Trypanosoma brucei gambiense: a multicentre, open-label, single-arm, phase 2/3 trial

(2022) Victor Kande Betu Kumeso et al.   LANCET INFECTIOUS DISEASES

The impact of AlphaFold Protein Structure Database on the fields of life sciences

(2022) Mihaly Varadi et al.   PROTEOMICS

Novel machine learning approaches revolutionize protein knowledge

(2022) Nicola Bordin et al.   TRENDS IN BIOCHEMICAL SCIENCES

Anti-Trypanosoma cruzi Activity of Metabolism Modifier Compounds

(2021) Nieves Martinez-Peinado et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Systematic functional analysis of Leishmania protein kinases identifies regulators of differentiation or survival

(2021) N. Baker et al.   Nature Communications

Repeat-Driven Generation of Antigenic Diversity in a Major Human Pathogen, Trypanosoma cruzi

(2021) Carlos Talavera-López et al.   Frontiers in Cellular and Infection Microbiology

Ubiquitination and the Proteasome as Drug Targets in Trypanosomatid Diseases

(2021) Marie-José Bijlmakers   Frontiers in Chemistry

New regimens of benznidazole monotherapy and in combination with fosravuconazole for treatment of Chagas disease (BENDITA): a phase 2, double-blind, randomised trial

(2021) Faustino Torrico et al.   LANCET INFECTIOUS DISEASES

In vitro susceptibility of Trypanosoma cruzi discrete typing units (DTUs) to benznidazole: A systematic review and meta-analysis

(2021) Andrea Vela et al.   PLoS Neglected Tropical Diseases

An Overview on Target-Based Drug Design against Kinetoplastid Protozoan Infections: Human African Trypanosomiasis, Chagas Disease and Leishmaniases

(2021) Violeta Kourbeli et al.   MOLECULES

Highly accurate protein structure prediction with AlphaFold

(2021) John Jumper et al.   NATURE

Amaryllidaceae plants: a potential natural resource for the treatment of Chagas disease

(2021) Nieves Martínez-Peinado et al.   Parasites & Vectors

Rate-of-Kill (RoK) assays to triage large compound sets for Chagas disease drug discovery: Application to GSK Chagas Box

(2021) Juan Cantizani et al.   PLoS Neglected Tropical Diseases

Local association of Trypanosoma cruzi chronic infection foci and enteric neuropathic lesions at the tissue micro-domain scale

(2021) Archie A. Khan et al.   PLoS Pathogens

From Magic Bullet to Magic Bomb: Reductive Bioactivation of Antiparasitic Agents

(2021) Sergio Wittlin et al.   ACS Infectious Diseases

Novel Purine Chemotypes with Activity against Plasmodium falciparum and Trypanosoma cruzi

(2021) Nieves Martinez-Peinado et al.   Pharmaceuticals

Identification of a Proteasome-Targeting Arylsulfonamide with Potential for the Treatment of Chagas’ Disease

(2021) Marta L. Lima et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

DNDI-6148: A Novel Benzoxaborole Preclinical Candidate for the Treatment of Visceral Leishmaniasis

(2021) Charles E. Mowbray et al.   JOURNAL OF MEDICINAL CHEMISTRY

Structural Optimization and Biological Activity of Pyrazole Derivatives: Virtual Computational Analysis, Recovery Assay and 3D Culture Model as Potential Predictive Tools of Effectiveness against Trypanosoma cruzi

(2021) Lorraine Martins Rocha Orlando et al.   MOLECULES

AlphaFold Protein Structure Database: massively expanding the structural coverage of protein-sequence space with high-accuracy models

(2021) Mihaly Varadi et al.   NUCLEIC ACIDS RESEARCH

VEuPathDB: the eukaryotic pathogen, vector and host bioinformatics resource center

(2021) Beatrice Amos et al.   NUCLEIC ACIDS RESEARCH

A resource for improved predictions of Trypanosoma and Leishmania protein three-dimensional structure

(2021) Richard John Wheeler   PLoS One

Live-imaging rate-of-kill compound profiling for Chagas disease drug discovery with a new automated high-content assay

(2021) Nina Svensen et al.   PLoS Neglected Tropical Diseases

Drug Target Validation of the Protein Kinase AEK1, Essential for Proliferation, Host Cell Invasion, and Intracellular Replication of the Human Pathogen Trypanosoma cruzi

(2021) Miguel A. Chiurillo et al.   Microbiology Spectrum

Estimated Research and Development Investment Needed to Bring a New Medicine to Market, 2009-2018

(2020) Olivier J. Wouters et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Computational approaches for drug discovery against trypanosomatid-caused diseases

(2020) Claudio A. Pereira et al.   PARASITOLOGY

A CRISPR/Cas9-riboswitch-Based Method for Downregulation of Gene Expression in Trypanosoma cruzi

(2020) Noelia Lander et al.   Frontiers in Cellular and Infection Microbiology

Chagas disease vaccine design: the search for an efficient Trypanosoma cruzi immune-mediated control

(2020) Augusto E. Bivona et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE

C57BL/6 α-1,3-Galactosyltransferase Knockout Mouse as an Animal Model for Experimental Chagas Disease

(2020) Edward Valencia Ayala et al.   ACS Infectious Diseases

Computational Drug Repositioning for Chagas Disease Using Protein-Ligand Interaction Profiling

(2020) Alfredo Juárez-Saldivar et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Discovery and Characterization of Clinical Candidate LXE408 as a Kinetoplastid-Selective Proteasome Inhibitor for the Treatment of Leishmaniases

(2020) Advait Nagle et al.   JOURNAL OF MEDICINAL CHEMISTRY

Effect of Posaconazole in an in vitro model of cardiac fibrosis induced by Trypanosoma cruzi

(2020) Lindice Mitie Nisimura et al.   MOLECULAR AND BIOCHEMICAL PARASITOLOGY

Challenges in Chagas Disease Drug Development

(2020) Amanda F. Francisco et al.   MOLECULES

Amaryllidaceae alkaloids with anti-Trypanosoma cruzi activity

(2020) Nieves Martinez-Peinado et al.   Parasites & Vectors

In Vivo Analysis of Trypanosoma cruzi Persistence Foci at Single-Cell Resolution

(2020) Alexander I. Ward et al.   mBio

Accelerating Therapeutics for Opportunities in Medicine: A Paradigm Shift in Drug Discovery

(2020) Izumi V. Hinkson et al.   Frontiers in Pharmacology

Animal models of Chagas disease and their translational value to drug development

(2020) Eric Chatelain et al.   Expert Opinion on Drug Discovery

Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019

(2020) Theo Vos et al.   LANCET

Host‐parasite dynamics in Chagas disease from systemic to hyper‐local scales

(2020) Damián Pérez‐Mazliah et al.   PARASITE IMMUNOLOGY

Trypanosoma Cruzi Genome: Organization, Multi-Gene Families, Transcription, and Biological Implications

(2020) Alfonso Herreros-Cabello et al.   Genes

Chagas Disease: Current View of an Ancient and Global Chemotherapy Challenge

(2020) Javier Martín-Escolano et al.   ACS Infectious Diseases

Dogs as a model for chemotherapy of Chagas disease and Leishmaniasis

(2020) Marta de Lana et al.   CURRENT PHARMACEUTICAL DESIGN

In Silico Identification of New Targets for Diagnosis, Vaccine, and Drug Candidates against Trypanosoma cruzi

(2020) Rafael Obata Trevisan et al.   DISEASE MARKERS

Discovery and Genetic Validation of Chemotherapeutic Targets for Chagas' Disease

(2019) Juan Felipe Osorio-Méndez et al.   Frontiers in Cellular and Infection Microbiology

American Trypanosomiasis (Chagas Disease)

(2019) Luis E. Echeverria et al.   INFECTIOUS DISEASE CLINICS OF NORTH AMERICA

Chemical Constituents of Anacardium occidentale as Inhibitors of Trypanosoma cruzi Sirtuins

(2019) Tanira Matutino Bastos et al.   MOLECULES

Preclinical candidate for the treatment of visceral leishmaniasis that acts through proteasome inhibition

(2019) Susan Wyllie et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Novel chemical starting points for drug discovery in leishmaniasis and Chagas disease

(2019) Irene Roquero et al.   International Journal for Parasitology-Drugs and Drug Resistance

State‐of‐the‐art CRISPR /Cas9 Technology for Genome Editing in Trypanosomatids

(2019) Noelia Lander et al.   JOURNAL OF EUKARYOTIC MICROBIOLOGY

TGF-β inhibitor therapy decreases fibrosis and stimulates cardiac improvement in a pre-clinical study of chronic Chagas’ heart disease

(2019) Roberto Rodrigues Ferreira et al.   PLoS Neglected Tropical Diseases

An Animal Model of Acute and Chronic Chagas Disease With the Reticulotropic Y Strain of Trypanosoma cruzi That Depicts the Multifunctionality and Dysfunctionality of T Cells

(2019) Jose Mateus et al.   Frontiers in Immunology

Investigation of a combination of amiodarone and itraconazole for treatment of American trypanosomiasis (Chagas disease) in dogs

(2019) Roy Madigan et al.   JAVMA-JOURNAL OF THE AMERICAN VETERINARY MEDICAL ASSOCIATION

Protozoan persister-like cells and drug treatment failure

(2019) Michael P. Barrett et al.   NATURE REVIEWS MICROBIOLOGY

Why hasn’t there been more progress in new Chagas disease drug discovery?

(2019) Alane Beatriz Vermelho et al.   Expert Opinion on Drug Discovery

In vitro models for investigation of the host-parasite interface - possible applications in acute Chagas disease

(2019) Natália Martins Breyner et al.   ACTA TROPICA

Chagas Disease: Chronic Chagas Cardiomyopathy

(2019) Natalia Giraldo Echavarría et al.   CURRENT PROBLEMS IN CARDIOLOGY

In silico repositioning of etidronate as a potential inhibitor of the Trypanosoma cruzi enolase

(2019) Edward A. Valera-Vera et al.   JOURNAL OF MOLECULAR GRAPHICS & MODELLING

Assessing the effectiveness of curative benznidazole treatment in preventing chronic cardiac pathology in experimental models of Chagas disease

(2018) Amanda Fortes Francisco et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

TGF-β Polymorphisms Are a Risk Factor for Chagas Disease

(2018) Roberto Rodrigues Ferreira et al.   DISEASE MARKERS

Chagas disease

(2018) José A Pérez-Molina et al.   LANCET

Treatment of adult chronic indeterminate Chagas disease with benznidazole and three E1224 dosing regimens: a proof-of-concept, randomised, placebo-controlled trial

(2018) Faustino Torrico et al.   LANCET INFECTIOUS DISEASES

Development of Trypanosoma cruzi in vitro assays to identify compounds suitable for progression in Chagas’ disease drug discovery

(2018) Lorna M. MacLean et al.   PLoS Neglected Tropical Diseases

Expanding the toolbox for Trypanosoma cruzi: A parasite line incorporating a bioluminescence-fluorescence dual reporter and streamlined CRISPR/Cas9 functionality for rapid in vivo localisation and phenotyping

(2018) Fernanda Cristina Costa et al.   PLoS Neglected Tropical Diseases

Spontaneous dormancy protects Trypanosoma cruzi during extended drug exposure

(2018) Fernando J Sánchez-Valdéz et al.   eLife

Innovation in neglected tropical disease drug discovery and development

(2018) Hong-Bo Weng et al.   Infectious Diseases of Poverty

A Magnetic Resonance Imaging Study of Intestinal Dilation in Trypanosoma cruzi–infected Mice Deficient in Nitric Oxide Synthase

(2018) Lars Ny et al.   AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE

The potent ITK/BTK inhibitor Ibrutinib is effective for the treatment of experimental visceral leishmaniasis caused by Leishmania donovani

(2018) Sanjay Varikuti et al.   JOURNAL OF INFECTIOUS DISEASES

Imaging the development of chronic Chagas disease after oral transmission

(2018) Michael D. Lewis et al.   Scientific Reports

Amiodarone for arrhythmia in patients with Chagas disease: A systematic review and individual patient data meta-analysis

(2018) Cinara Stein et al.   PLoS Neglected Tropical Diseases

Efficacy of sertraline against Trypanosoma cruzi: an in vitro and in silico study

(2018) Daiane Dias Ferreira et al.   JOURNAL OF VENOMOUS ANIMALS AND TOXINS INCLUDING TROPICAL DISEASES

Host-Directed Drug Therapies for Neglected Tropical Diseases Caused by Protozoan Parasites

(2018) Sanjay Varikuti et al.   Frontiers in Microbiology

Synthesis and antitrypanosomal activities of novel pyridylchalcones

(2017) Avninder S. Bhambra et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Phenotypic screening approaches for Chagas disease drug discovery

(2017) Eric Chatelain et al.   Expert Opinion on Drug Discovery

Nonhuman Primates and Translational Research—Cardiovascular Disease

(2017) Laura A Cox et al.   ILAR JOURNAL

In silico identification of inhibitors of ribose 5-phosphate isomerase from Trypanosoma cruzi using ligand and structure based approaches

(2017) Vanessa de V. C. Sinatti et al.   JOURNAL OF MOLECULAR GRAPHICS & MODELLING

Benznidazole and Posaconazole in Eliminating Parasites in Asymptomatic  T. Cruzi Carriers

(2017) Carlos A. Morillo et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Beneficial immunomodulatory and neuro digestive effect in Trypanosoma cruzi infection after Lycopodium clavatum 13c treatment

(2017) Camila Fernanda Brustolin Aleixo et al.   MICROBIAL PATHOGENESIS

Cynomolgus macaques naturally infected with Trypanosoma cruzi-I exhibit an overall mixed pro-inflammatory/modulated cytokine signature characteristic of human Chagas disease

(2017) Danielle Marquete Vitelli-Avelar et al.   PLoS Neglected Tropical Diseases

Comparative transcriptome profiling of virulent and non-virulent Trypanosoma cruzi underlines the role of surface proteins during infection

(2017) A. Trey Belew et al.   PLoS Pathogens

SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules

(2017) Antoine Daina et al.   Scientific Reports

Rapid Chagas Disease Drug Target Discovery Using Directed Evolution in Drug-Sensitive Yeast

(2016) Sabine Ottilie et al.   ACS Chemical Biology

Proteins involved on TGF-β pathway are up-regulated during the acute phase of experimental Chagas disease

(2016) Roberto Rodrigues Ferreira et al.   IMMUNOBIOLOGY

Innovation in the pharmaceutical industry: New estimates of R&D costs

(2016) Joseph A. DiMasi et al.   JOURNAL OF HEALTH ECONOMICS

Proteasome inhibition for treatment of leishmaniasis, Chagas disease and sleeping sickness

(2016) Shilpi Khare et al.   NATURE

Identification of Trypanocidal Activity for Known Clinical Compounds Using a New Trypanosoma cruzi Hit-Discovery Screening Cascade

(2016) Manu De Rycker et al.   PLoS Neglected Tropical Diseases

Here, There, and Everywhere: The Ubiquitous Distribution of the Immunosignaling Molecule Lysophosphatidylcholine and Its Role on Chagas Disease

(2016) Mário Alberto C. Silva-Neto et al.   Frontiers in Immunology

Limited Ability of Posaconazole To Cure both Acute and Chronic Trypanosoma cruzi Infections Revealed by Highly SensitiveIn VivoImaging

(2015) Amanda Fortes Francisco et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Design, synthesis and biological evaluation of quinazoline derivatives as anti-trypanosomatid and anti-plasmodial agents

(2015) César Mendoza-Martínez et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Translational challenges of animal models in Chagas disease drug development: a review

(2015) Eric Chatelain et al.   Drug Design Development and Therapy

New Compound Sets Identified from High Throughput Phenotypic Screening Against Three Kinetoplastid Parasites: An Open Resource

(2015) Imanol Peña et al.   Scientific Reports

Development of a Fluorescence-based Trypanosoma cruzi CYP51 Inhibition Assay for Effective Compound Triaging in Drug Discovery Programmes for Chagas Disease

(2015) Jennifer Riley et al.   PLoS Neglected Tropical Diseases

Automated High-Content Assay for Compounds Selectively Toxic to Trypanosoma cruzi in a Myoblastic Cell Line

(2015) Julio Alonso-Padilla et al.   PLoS Neglected Tropical Diseases

HepG2 cells as an in vitro model for evaluation of cytochrome P450 induction by xenobiotics

(2014) Jong Min Choi et al.   ARCHIVES OF PHARMACAL RESEARCH

Bioluminescence imaging of chronicTrypanosoma cruziinfections reveals tissue-specific parasite dynamics and heart disease in the absence of locally persistent infection

(2014) Michael D. Lewis et al.   CELLULAR MICROBIOLOGY

Drug discovery for Chagas disease should consider Trypanosoma cruzi strain diversity

(2014) Bianca Zingales et al.   MEMORIAS DO INSTITUTO OSWALDO CRUZ

Randomized Trial of Posaconazole and Benznidazole for Chronic Chagas' Disease

(2014) Israel Molina et al.   NEW ENGLAND JOURNAL OF MEDICINE

Anti-Trypanosoma cruzi and anti-leishmanial activity by quinoxaline-7-carboxylate 1,4-di-N-oxide derivatives

(2014) Juan Carlos Villalobos-Rocha et al.   PARASITOLOGY RESEARCH

Structural and Functional Analysis of a Platelet-Activating Lysophosphatidylcholine of Trypanosoma cruzi

(2014) Felipe Gazos-Lopes et al.   PLoS Neglected Tropical Diseases

High Throughput Screening for Anti–Trypanosoma cruzi Drug Discovery

(2014) Julio Alonso-Padilla et al.   PLoS Neglected Tropical Diseases

Regulators of Trypanosoma brucei Cell Cycle Progression and Differentiation Identified Using a Kinome-Wide RNAi Screen

(2014) Nathaniel G. Jones et al.   PLoS Pathogens

Approaches to Protozoan Drug Discovery: Phenotypic Screening

(2013) Melissa L. Sykes et al.   JOURNAL OF MEDICINAL CHEMISTRY

Use of clomipramine as chemotherapy of the chronic phase of Chagas disease

(2013) ROMINA FAURO et al.   PARASITOLOGY

Improved Completion Rates and Characterization of Drug Reactions with an Intensive Chagas Disease Treatment Program in Rural Bolivia

(2013) Jeffrey A. Tornheim et al.   PLoS Neglected Tropical Diseases

Bisphosphonate metal complexes as selective inhibitors of Trypanosoma cruzi farnesyl diphosphate synthase

(2012) Bruno Demoro et al.   DALTON TRANSACTIONS

Evaluation of benznidazole treatment combined with nifurtimox, posaconazole or AmBisome® in mice infected with Trypanosoma cruzi strains

(2012) Sabrina Cencig et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Cardiomyopathy prognosis after benznidazole treatment in chronic canine Chagas' disease

(2012) F. M. Santos et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

The emerging role of amiodarone and dronedarone in Chagas disease

(2012) Gustavo Benaim et al.   Nature Reviews Cardiology

Fexinidazole: A Potential New Drug Candidate for Chagas Disease

(2012) Maria Terezinha Bahia et al.   PLoS Neglected Tropical Diseases

Identification of small-molecule inhibitors of Trypansoma cruzi replication

(2011) Andrew R. Germain et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Shotgun Sequencing Analysis of Trypanosoma cruzi I Sylvio X10/1 and Comparison with T. cruzi VI CL Brener

(2011) Oscar Franzén et al.   PLoS Neglected Tropical Diseases

Image-Based High-Throughput Drug Screening Targeting the Intracellular Stage of Trypanosoma cruzi, the Agent of Chagas' Disease

(2010) J. C. Engel et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

ECG Detection of Murine Chagasic Cardiomyopathy

(2010) Christopher S. Eickhoff et al.   JOURNAL OF PARASITOLOGY

Chagas disease and stroke

(2010) Francisco Javier Carod-Artal et al.   LANCET NEUROLOGY

In vitro and in vivo experimental models for drug screening and development for Chagas disease

(2010) Alvaro José Romanha et al.   MEMORIAS DO INSTITUTO OSWALDO CRUZ

High-content imaging for automated determination of host-cell infection rate by the intracellular parasite Trypanosoma cruzi

(2010) L.L. Nohara et al.   PARASITOLOGY INTERNATIONAL

In Vitro and In Vivo High-Throughput Assays for the Testing of Anti-Trypanosoma cruzi Compounds

(2010) Adriana M. C. Canavaci et al.   PLoS Neglected Tropical Diseases

Coronary Microvascular Disease in Chronic Chagas Cardiomyopathy Including an Overview on History, Pathology, and Other Proposed Pathogenic Mechanisms

(2010) Marcos A. Rossi et al.   PLoS Neglected Tropical Diseases

Retention and Loss of RNA Interference Pathways in Trypanosomatid Protozoans

(2010) Lon-Fye Lye et al.   PLoS Pathogens

Chagas disease in Spain, the United States and other non-endemic countries

(2009) Joaquim Gascon et al.   ACTA TROPICA

TriTrypDB: a functional genomic resource for the Trypanosomatidae

(2009) Martin Aslett et al.   NUCLEIC ACIDS RESEARCH

Identification of Three Classes of Heteroaromatic Compounds with Activity against Intracellular Trypanosoma cruzi by Chemical Library Screening

(2009) Esther Bettiol et al.   PLoS Neglected Tropical Diseases

Fibrosis and Hypertrophy Induced byTrypanosoma cruziin a Three‐Dimensional Cardiomyocyte‐Culture System

(2008) Luciana Ribeiro Garzoni et al.   JOURNAL OF INFECTIOUS DISEASES

Natural Chagas disease in four baboons

(2008) Jeff T. Williams et al.   JOURNAL OF MEDICAL PRIMATOLOGY